Celldex Pharmaceuticals stopped investigating its mast cell-targeting antibody barzolvolimab in prurigo nodularis after a Phase 2 study missed efficacy on all endpoints, the company disclosed. The program discontinuation follows barzolvolimab’s broader chronic itch development plans and raises questions about the strength of the upcoming readouts investors were awaiting, particularly as the company prepares for additional dermatology decision points. Celldex indicated it will end development in the indication where the trial failed and will focus on other programs, while analysts have cited the poor outcome as a reminder of how difficult mast-cell biology can be to translate into durable clinical benefit. For the sector, the move further concentrates risk in chronic itch pipelines and increases pressure for stronger biomarker strategies and patient selection.